Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer (Q36032963)

11 August 2017

Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer (English)

1 reference

non-small-cell lung carcinoma

11 August 2017

1 reference

1 reference

Therese Phillips

1

1 reference

11 August 2017

Pauline Simmons

2

1 reference

11 August 2017

Hector D Inzunza

3

1 reference

11 August 2017

John Cogswell

4

1 reference

11 August 2017

James Novotny

5

1 reference

11 August 2017

Clive Taylor

6

1 reference

11 August 2017

Xiaoling Zhang

7

1 reference

11 August 2017

25 August 2015

1 reference

Applied Immunohistochemistry & Molecular Morphology

11 August 2017

1 reference

11 August 2017

23

1 reference

11 August 2017

8

1 reference

11 August 2017

541-549

1 reference

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

Nivolumab in previously untreated melanoma without BRAF mutation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

Programmed death ligand-1 expression in non-small cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

A TALE nuclease architecture for efficient genome editing

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561627

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26317305

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26317305

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/PAI.0000000000000256

1 reference

11 August 2017

1 reference

11 August 2017

1 reference